Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 3 57-3, 2005, Pages

  Alpert, Norman R ^a   Mohiddin, Saidi A ^b,d   Tripodi, Dorothy ^b   Jacobson Hatzell, Jacqueline ^c   Vaughn Whitley, Kelly ^c   Brosseau, Christine ^a   Warshaw, David M ^a   Fananapazir, Lameh ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Dakota Cardiovascular   (United States)

^d Bldg 10 CRC ^*  (United States)

Author keywords

Cardiomyopathy; Hypertrophy; Motility assay; Penetrance

Indexed keywords

ACTIN; GLYCINE; LEUCINE; LYSINE; MYOSIN; MYOSIN HEAVY CHAIN; VALINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DOSE RESPONSE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FEMALE; GENE MUTATION; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART LEFT VENTRICLE; HEART PERFORMANCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MOLECULAR BIOLOGY; MYH7 GENE; PENETRANCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

ACTINS; BIOPSY; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; FAMILY LEAVE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS; PEDIGREE; PENETRANCE; PHENOTYPE;

EID: 13944253657     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00650.2004     Document Type: Article

References (37)

1. Alpert NR, Brosseau C, Federico A, Krenz M, Robbins J, and Warshaw DM. Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol Heart Circ Physiol 283: H1446-H1454, 2002.
2. Ashrafian H, Redwood C, Blair E, and Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19: 263-268, 2003.
3. Cuda G, Fananapazir L, Epstein ND, and Sellers JR. The in vitro motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 18: 275-283, 1997.
4. Cuda G, Fananapazir L, Zhu WS, Sellers JR, and Epstein ND. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J Clin Invest 91: 2861-2865, 1993.
5. Epstein ND, Cohn GM, Cyran F, and Fananapazir L. Differences in clinical expression of hypertrophie cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation 86: 345-352, 1992.
6. Erdmann J, Daehmlow S, Wischke S, Senyuva M, Werner U, Raible J, Tanis N, Dyachenko S, Hummel M, Hetzer R, and Regitz-Zagrosek V. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet 64: 339-349, 2003.
7. Fatkin D, Christe ME, Aristizabal O, McConnell BK, Srinivasan S, Schoen FJ, Seidman CE, Turnhull DH, and Seidman JG. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. J Clin Invest 103: 147-153, 1999.
8. Fatkin D and Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82: 945-980, 2002.
9. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Abmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R, and Hassan AS. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344: 1823-1831, 2001.
10. Jeschke B, Uhl K, Weist B, Schroder D, Meitinger T, Dohlemann C, and Vosberg HP, A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes. Hum Genet 102: 299-304, 1998.
11. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, and Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343: 1688-1696, 2000.
12. Lauzon AM, Fagnant PM, Warshaw DM, and Try bus KM. Coiled-coil unwinding at the smooth muscle myosin head-rod junction is required for optimal mechanical performance. Biophys J 80: 1900-1904, 2001.
13. Lowey S. Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 12: 348-354, 2002.
14. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 17: 242-252, 2002.
15. Marian AJ and Roberts R. Familial hypertrophic cardiomyopathy: a paradigm of the cardiac hypertrophic response to injury. Ann Med 30, Suppl 1: 24-32, 1998.
16. Maron BJ and Spirito P. Implications of left ventricular remodeling in hypertrophie cardiomyopathy. Am J Cardiol 81: 1339-1344, 1998.
17. McConnell BK, Jones KA, Fatkin D, Arroyo LH, Lee RT, Aristizabal O, Turnbull DH, Georgakopoulos D, Kass D, Bond M, Niimura H, Schoen FJ, Conner D, Fischman DA, Seidman CE, and Seidman JG. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 104: 1235-1244, 1999.
18. Mohiddin SA, Begley DA, McLam E, Cardoso JP, Winkler JB, Sellers JR, and Fananapazir L. Utility of genetic screening in hypertrophic cardiomyopathy: prevalence and significance of novel and double (homozygous and heterozygous) β-myosin mutations. Genet Test 7: 21-27, 2003.
19. Monemi M, Eriksson PO, Kadi F, Butler-Browne GS, and Thornell LE. Opposite changes in myosin heavy chain composition of human masseter and biceps brachii muscles during aging. J Muscle Res Cell Motil 20: 351-361, 1999.
20. Murphy CT and Spudich JA. Variable surface loops and myosin activity; accessories to a motor. J Muscle Res Cell Motil 21: 139-151, 2000.
21. Nanni L, Pieroni M, Chimenti C, Simionati B, Zimbello R, Maseri A, Frustaci A, and Lanfranchi G. Hypertrophic cardiomyopathy: two homozygous cases with "typical" hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy. Biochem Biophys Res Commun 309: 391-398, 2003.
22. Nguyen TT, Hayes E, Mulleri LA, Leavitt BJ, ter Keurs HE, Alpert NR, and Warshaw DM. Maximal actomyosin ATPase activity and in vitro myosin motility are unaltered in human mitral regurgitation heart failure. Circ Res 79: 222-226, 1996.
23. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, and Warshaw DM. R403Q and L908V mutant β-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil 21: 609-620, 2000.
24. Pardee JD and Spudich JA. Purification of muscle actin. Methods Cell Biol 24: 271-289, 1982.
25. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, and Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227-2232, 2003.
26. Richard P, Charron P, Leclercq C, Ledeuil C, Carrier L, Dubourg O, Desnos M, Bouhour JB, Schwartz K, Daubert JC, Komajda M, and Hainque B. Homozygotes for a R869G mutation in the β-myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 32: 1575-1583, 2000.
27. Richard P, Isnard R, Carrier L, Dubourg O, Donatien Y, Mathieu B, Bonne G, Gary F, Charron P, Hagege M, Komajda M, Schwartz K, and Hainque B. Double heterozygosity for mutations in the β-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet 36: 542-545, 1999.
28. Sata M and Ikebe M. Functional analysis of the mutations in the human cardiac β-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest 98: 2866-2873, 1996.
29. Seidman JG and Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104: 557-567, 2001.
30. Spirito P, Maron BJ, Bonow RO, and Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 60: 123-129, 1987.
31. Sweeney HL, Straceski AJ, Leinwand LA, Tikunov BA, and Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem 269: 1603-1605, 1994.
32. Tyska MJ, Dupuis DE, Guilford WH, Patlak JB, Waller GS, Trybus KM, Warshaw DM, and Lowey S. Two heads of myosin are better than one for generating force and motion. Proc Natl Acad Sci USA 96: 4402-4407, 1999.
33. Tyska MJ, Hayes E, Giewat M, Seidman CE, Seidman JG, and Warshaw DM. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 86: 737-744, 2000.
34. 34: Vale RD and Milligan RA. The way things move: looking under the hood of molecular motor proteins. Science 288: 88-95, 2000.
35. Warshaw DM, Desrosiers JM, Work SS, and Trybus KM. Smooth muscle myosin cross-bridge interactions modulate actin filament sliding velocity in vitro. J Cell Biol 111: 453-463, 1990.
36. Work SS and Warshaw DM. Computer-assisted tracking of actin filament motility. Anal Biochem 202: 275-285, 1992.
37. Yamashita H, Tyska MJ, Warshaw DM, Lowey S, and Trybus KM. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem 275: 28045-28052, 2000.